تثبيت وحدة حرية التحويل!
تثبيت وحدة حرية التحويل!
تثبيت وحدة حرية التحويل!
|
تثبيت وحدة حرية التحويل!
- Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases The company’s lead product candidate, nomlabofusp (previously known as CTI-1601), is currently being evaluated in a Phase 2 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive
- News – Larimar Therapeutics
April 30, 2026 Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia > BALA CYNWYD, Pa , April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases
- Pipeline – Larimar Therapeutics
Pipeline Larimar’s lead compound, nomlabofusp, is currently being evaluated in a Phase 2 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease The company also plans to use its proprietary protein replacement therapy platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular
- Investors | Larimar Therapeutics, Inc.
Larimar’s nomlabofusp development program was also selected by the FDA to participate in its START (Support for clinical Trials Advancing Rare Disease Therapeutics) pilot program, which is designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases
- Company Overview – Larimar Therapeutics
Company Overview Larimar Therapeutics, based in the Philadelphia area, is committed to discovering and developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside cells to treat devastating rare diseases that currently have limited or no treatments available
- Leadership – Larimar Therapeutics
Maha Saad, PhD, MBA > Vice President, Pharmacovigilance (PV) and Product Safety
- Scientific Approach – Larimar Therapeutics
Scientific Approach Our Science Larimar Therapeutics’ proprietary protein replacement therapy platform has the potential to provide disease-modifying therapies that are intended to deliver missing or deficient proteins inside the machinery of cells to treat devastating rare diseases that currently have limited or no treatments available
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 . . .
About Larimar Therapeutics Larimar Therapeutics, Inc (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia
|
|
|